MedTrace Logo

Feasibility of Cannabidiol for the Treatment of Long COVID

NCT04997395 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-01-19

No results posted yet for this study

Summary

This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID. The primary aim is to assess the feasibility of recruiting and retaining individuals diagnosed with Long COVID into a treatment trial of medicinal cannabis, as well as assessing the safety and tolerability of a dominant medicinal cannabis in this population. The secondary aim is to determine the effect of a CBD dominant medicinal cannabis on symptoms associated with Long COVID.

Conditions

Interventions

DRUG

MediCabilis Cannabis sativa 50

Already described

Sponsors & Collaborators

  • Drug Science, UK

    collaborator OTHER

  • Bod Australia

    lead INDUSTRY

Principal Investigators

  • Elizabeth Iveson · Steps Neurorehabilitation Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2023-01-06
Completion
2023-01-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997395 on ClinicalTrials.gov